1
Loftsson Thorsteinn: Cyclodextrin complexation.. Loftsson Thorsteinn, January 19, 1994: EP0579435-A1 (56 worldwide citation)

The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile drug, comprising combining from about 0.1 to about 70% (weight/volume) of a cyclodextrin and from about 0.001 to about 5% (weight/volume) of a pharmaceutically acceptable, pharmacol ...


2
Loftsson Thorsteinn, Stefansson Einar: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, Loftsson Thorsteinn, Stefansson Einar, HEDLEY Nicholas James Matthew, February 1, 2007: WO/2007/012974 (2 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin com&rgr;lex( ...


3
Loftsson Thorsteinn, Bodor Nicholas: Systeme dadministration transdermique, Transdermal delivery system. Key Pharmaceuticals, Loftsson Thorsteinn, Bodor Nicholas, SWABEY OGILVY RENAULT, March 5, 1991: CA1280974

ABSTRACT OF THE DISCLOSURE Pharmaceutical preparations comprised of a pharmaceuticallyactive ingredient and a carrier which comprises a percutaneouspenetration enhancer comprised of 2-ethyl-1, 3-hexanediol and/oroleic acid is disclosed. The 2-ethyl-1, 3-hexanediolmay be present in an amount in the r ...


4
Loftsson Thorsteinn, Masson Mar: A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes. Astrazeneca, Loftsson Thorsteinn, Masson Mar, GLOBAL INTELLECTUAL PROPERTY, March 6, 2003: WO/2003/017921

This invention relates to a new method to improve the complexation efficacy of a basic active substance and a cyclodextrin using an acidic volatile substance. The invention further relates to a method to prepare high-energy complexes of a basic active substance and a cyclodextrin that form super-sat ...


5
LOFTSSON Thorsteinn: [fr] SUPPOSITOIRES ENROBÉS, [en] COATED SUPPOSITORIES. LOFTSSON Thorsteinn, LIPID PHARMACEUTICALS EHF, ARNASON FAKTOR, March 14, 2013: WO/2013/035113

[en] The invention relates to coating of suppositories containing free unsaturated fatty acid, fatty acid ethyl ester and fatty acid monoglyceride that are susceptible to oxidative degradation. The coating retards oxidative degradation of unsaturated fatty acids and gives the suppository a non-oily ...



Click the thumbnails below to visualize the patent trend.